Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

被引：478

作者：

Crews, K. R. ^{[1
]}

Gaedigk, A. ^{[2
,3
]}

Dunnenberger, H. M. ^{[1
]}

Leeder, J. S. ^{[2
,3
]}

Klein, T. E. ^{[4
]}

Caudle, K. E. ^{[1
]}

Haidar, C. E. ^{[1
]}

Shen, D. D. ^{[5
,6
]}

Callaghan, J. T. ^{[7
,8
]}

Sadhasivam, S. ^{[9
,10
]}

Prows, C. A. ^{[11
,12
]}

Kharasch, E. D. ^{[13
]}

Skaar, T. C. ^{[7
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Childrens Mercy Hosp & Clin, Div Clin Pharmacol & Therapeut Innovat, Kansas City, MO USA

[3] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[4] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[5] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA

[6] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA

[7] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA

[8] RLR VA Med Ctr, Dept Vet Affairs, Indianapolis, IN USA

[9] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA

[10] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA

[11] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA

[12] Cincinnati Childrens Hosp Med Ctr, Div Patient Serv, Cincinnati, OH 45229 USA

[13] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 04期

基金：

美国医疗保健研究与质量局;

关键词：

CYP2D6 ACTIVITY SCORE; BREAST-FED NEONATE; ULTRARAPID-METABOLISM; MORPHINE FORMATION; CANCER-PATIENTS; OXYCODONE; TRAMADOL; PHARMACOKINETICS; PHENOTYPE; PHARMACODYNAMICS;

D O I：

10.1038/clpt.2013.254

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

引用

页码：376 / 382

页数：7

共 40 条

[1]

Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance [J].

Allegaert, Karel ;

Rochette, Alain ;

Veyckemans, Francis .

PEDIATRIC ANESTHESIA, 2011, 21 (03) :266-273

[2]

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study [J].

Andreassen, Trine Naalsund ;

Eftedal, Ingrid ;

Klepstad, Pal ;

Davies, Andrew ;

Bjordal, Kristin ;

Lundstrom, Staffan ;

Kaasa, Stein ;

Dale, Ola .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (01) :55-64

[3]

[Anonymous], 2013, FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safetyemphasizing that accidental exposure to used patches can cause death

[4]

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life [J].

Blake, M. J. ;

Gaedigk, A. ;

Pearce, R. E. ;

Bomgaars, L. R. ;

Christensen, M. L. ;

Stowe, C. ;

James, L. P. ;

Wilson, J. T. ;

Kearns, G. L. ;

Leeder, J. S. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :510-516

[5]

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients [J].

Borges, Silvana ;

Desta, Zeruesenay ;

Jin, Yan ;

Faouzi, Azzouz ;

Robarge, Jason D. ;

Philip, Santosh ;

Nguyen, Anne ;

Stearns, Vered ;

Hayes, Daniel ;

Rae, James M. ;

Skaar, Todd C. ;

Flockhart, David A. ;

Li, Lang .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04) :450-458

[6]

Codeine, Ultrarapid-Metabolism Genotype, and Postoperative Death [J].

Ciszkowski, Catherine ;

Madadi, Parvaz ;

Phillips, Michael S. ;

Lauwers, Albert E. ;

Koren, Gideon .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :827-828

[7]

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype [J].

Crews, K. R. ;

Gaedigk, A. ;

Dunnenberger, H. M. ;

Klein, T. E. ;

Shen, D. D. ;

Callaghan, J. T. ;

Kharasch, E. D. ;

Skaar, T. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) :321-326

[8]

Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine [J].

Dalen, P ;

Frengell, C ;

Dahl, ML ;

Sjoqvist, F .

THERAPEUTIC DRUG MONITORING, 1997, 19 (05) :543-544

[9]

Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy [J].

Davis, MP ;

Varga, J ;

Dickerson, D ;

Walsh, D ;

LeGrand, SB ;

Lagman, R .

SUPPORTIVE CARE IN CANCER, 2003, 11 (02) :84-92

[10]

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation [J].

Eckhardt, K ;

Li, SX ;

Ammon, S ;

Schänzle, G ;

Mikus, G ;

Eichelbaum, M .

PAIN, 1998, 76 (1-2) :27-33

← 1 2 3 4 →